The DECISIVE study: defining beta-lactam concentration in intensive care unit patients – the pharmacokinetics of piperacillin and meropenem in critically ill patients with conserved renal function

The DECISIVE study: defining beta-lactam concentration in intensive care unit patients – the pharmacokinetics of piperacillin and meropenem in critically ill patients with conserved renal function

Bibliographic Details
Main Authors:	M. Abdul-Aziz, M. Rozali, M. Othman-Jailani, A. Abd Rahman, H. Sulaiman, N. Atiya, S. Adiraju, S. Wallis, W. Wan Mat, M. Mazlan, M. Jamaluddin, M. Hasan, M. Mat-Nor, J. Roberts
Format:	Article
Language:	English
Published:	Elsevier 2020-02-01
Series:	Journal of Infection and Public Health
Online Access:	http://www.sciencedirect.com/science/article/pii/S1876034120301301

Similar Items

Pharmacokinetic Analysis of Meropenem and Piperacillin in Critically-Ill Patients Requiring Continuous Ven-Venous Hemodiafiltration
by: Brandon Ferlas, et al.
Published: (2015-01-01)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock
by: Yang Sun, et al.
Published: (2023-06-01)

Plasma & subcutaneous tissue pharmacokinetics of piperacillin in a large cohort of critically ill patients with sepsis
by: Abdul Aziz, Mohd. Hafiz, et al.
Published: (2014)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
by: Gan Y, et al.
Published: (2023-06-01)

Population pharmacokinetics of meropenem in critically ill infant patients
by: Wanlika Yonwises, et al.
Published: (2021-10-01)

Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn
by: Daniel J. Selig, et al.
Published: (2022-05-01)

Antistaphylococcal Efficacy of Cefepime, Meropenem, and Piperacillin-Tazobactam in Patients with Polymicrobial Infection with MSSA Bacteremia or Pneumonia
by: Laila M. Najia, et al.
Published: (2023-01-01)

Population Pharmacokinetics of Piperacillin in Non-Critically Ill Patients with Bacteremia Caused by Enterobacteriaceae
by: Vicente Merino-Bohórquez, et al.
Published: (2021-03-01)

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections
by: Pasquale Maria Berrino, et al.
Published: (2023-08-01)

Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation
by: Cristina Sanches, et al.
Published: (2022-03-01)

Therapeutic Drug Monitoring of Meropenem and Piperacillin in Critical Illness—Experience and Recommendations from One Year in Routine Clinical Practice
by: Christina Scharf, et al.
Published: (2020-03-01)

Meropenem versus piperacillin/tazobactam with or without immunoglobulin as second-line therapy for febrile neutropenia in pediatric patients
by: Ryoji Kobayashi, et al.
Published: (2018-08-01)

Meropenem Target Attainment and Population Pharmacokinetics in Critically Ill Septic Patients with Preserved or Increased Renal Function
by: Gijsen M, et al.
Published: (2022-01-01)

Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation
by: Dong-Hwan Lee, et al.
Published: (2021-11-01)

Pharmacokinetics and Pharmacodynamics of Meropenem by Extended or Continuous Infusion in Low Body Weight Critically Ill Patients
by: Sonia Luque, et al.
Published: (2021-06-01)

External Evaluation of Population Pharmacokinetic Models to Inform Precision Dosing of Meropenem in Critically Ill Patients
by: Nan Yang, et al.
Published: (2022-05-01)

Impact of cumulative fluid balance on the pharmacokinetics of extended infusion meropenem in critically ill patients with sepsis
by: Renata Černá Pařízková, et al.
Published: (2021-07-01)

Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit
by: Abdul-Aziz, M.H., et al.
Published: (2015)

The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
by: Ahmed A. Abulfathi, et al.
Published: (2021-06-01)

Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study
by: Stephan Braune, et al.
Published: (2018-01-01)

Pharmacokinetics and Monte Carlo Simulation of Meropenem in Critically Ill Adult Patients Receiving Extracorporeal Membrane Oxygenation
by: Jae Ha Lee, et al.
Published: (2021-11-01)

Comparison of the incidence of acute kidney injury during treatment with vancomycin in combination with piperacillin–tazobactam or with meropenem
by: Majed S. Al Yami
Published: (2017-11-01)

Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis
by: Abdul-Aziz, M.H., et al.
Published: (2016)

Effect of Different Piperacillin-Tazobactam Dosage Regimens on Synergy of the Combination with Tobramycin against <i>Pseudomonas aeruginosa</i> for the Pharmacokinetics of Critically Ill Patients in a Dynamic Infection Model
by: Jessica R. Tait, et al.
Published: (2022-01-01)

Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study
by: Chun Liu, et al.
Published: (2023-03-01)

Use of cefepime, meropenem, or piperacillin/tazobactam as initial treatment for febrile neutropenia in patients with hematological malignancy — a real-life experience
by: Najmul Karim, et al.
Published: (2022-08-01)

The DALI study: defining antibiotic levels in intensive care unit patients: prolonged infusion of beta-lactam antibiotics in critically ill patients
by: Abdul Aziz, Mohd. Hafiz, et al.
Published: (2013)

Acute-on-chronic liver failure alters meropenem pharmacokinetics in critically ill patients with continuous hemodialysis: an observational study
by: Jörn Grensemann, et al.
Published: (2020-04-01)

Piperacillin/Tazobactam and Meropenem Use Increases the Risks for Acute Graft Rejection Following First Kidney Transplantation
by: Dayana Nasr, et al.
Published: (2022-05-01)

Continuous beta-lactam infusion in critically ill patients: the clinical evidence
by: Abdul Aziz, Mohd. Hafiz, et al.
Published: (2012)

Pharmacokinetics–pharmacodynamics issues relevant for the clinical use of beta-lactam antibiotics in critically ill patients
by: Rui Pedro Veiga, et al.
Published: (2018-09-01)

Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: a cost-utility analysis comparing meropenem with piperacillin/tazobactam.
by: Edwards, S, et al.
Published: (2012)

Treating pneumonia in critical care in the United Kingdom following failure of initial antibiotic: A cost-utility analysis comparing meropenem with piperacillin/tazobactam
by: Edwards, S, et al.
Published: (2012)

Dose Optimization of Meropenem in Patients on Veno-Arterial Extracorporeal Membrane Oxygenation in Critically Ill Cardiac Patients: Pharmacokinetic/Pharmacodynamic Modeling
by: Soyoung Kang, et al.
Published: (2022-11-01)

Population Pharmacokinetics and Dosing Optimization of Piperacillin-Tazobactam in Critically Ill Patients on Extracorporeal Membrane Oxygenation and the Influence of Concomitant Renal Replacement Therapy
by: Jongsung Hahn, et al.
Published: (2021-12-01)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis
by: Matthias Gijsen, et al.
Published: (2021-06-01)

Drug-induced hypersensitivity syndrome with high procalcitonin levels due to piperacillin/tazobactam and meropenem: A case report
by: Gao Song, et al.
Published: (2022-10-01)

Impact of Various Estimated Glomerular Filtration Rate Equations on the Pharmacokinetics of Meropenem in Critically Ill Adults
by: Erin F. Barreto, PharmD, MSc, et al.
Published: (2023-12-01)

Piperacillin/Tazobactam in critically ill morbidly obese patients: A case series: The first One‐Centre experience with TDM
by: M. Mieresova, et al.
Published: (2023-03-01)

An Appraisal of the Pharmacokinetic and Pharmacodynamic Properties of Meropenem-Vaborbactam
by: Eric Wenzler, et al.
Published: (2020-10-01)